- Home
- PLSE vs ARQT Comparison
PLSE vs ARQT Comparison
Compare PLSE & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PLSE | ARQT |
|---|---|---|
| Founded | 2014 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 3.5B |
| IPO Year | 2015 | 2020 |
Fundamental Metrics
Financial Performance| Metric | PLSE | ARQT |
|---|---|---|
| Price | $50.31 | $23.87 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | $22.00 | ★ $34.00 |
| AVG Volume (30 Days) | 390.4K | ★ 1.7M |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 88.79 |
| EPS | N/A | ★ 0.03 |
| Revenue | N/A | ★ $376,072,000.00 |
| Revenue This Year | $840.00 | $34.85 |
| Revenue Next Year | $287.54 | $29.39 |
| P/E Ratio | ★ N/A | $795.00 |
| Revenue Growth | N/A | ★ 91.34 |
| 52 Week Low | $12.56 | $15.13 |
| 52 Week High | $50.90 | $31.77 |
Technical Indicators
Market Signals| Indicator | PLSE | ARQT |
|---|---|---|
| Relative Strength Index (RSI) | 71.66 | 36.04 |
| Support Level | $24.27 | $22.49 |
| Resistance Level | N/A | $23.87 |
| Average True Range (ATR) | 2.75 | 0.93 |
| MACD | -0.23 | -0.21 |
| Stochastic Oscillator | 86.54 | 15.33 |
Price Performance
Historical ComparisonAbout PLSE Pulse Biosciences Inc (DE)
Pulse Biosciences Inc is a novel bioelectric medicine company committed to health innovation using its patented Nano-Pulse Stimulation technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. NPS technology, also referred to as Nanosecond Pulsed Field Ablation (nsPFA) technology delivers nanosecond pulses of electrical energy to nonthermally clear cells while sparing adjacent noncellular tissue.
About ARQT Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases.